Clin Exp Rheumatol:表面活性蛋白D与抗MDA5抗体-间质性肺病的3个月死亡率相关

2020-04-26 xiangting MedSci原创

血清生物标志物升高与DM/PM-ILD相关,并且MDA5-ILD和ARS-ILD之间存在差异。

这项研究旨在探讨基质金属蛋白酶7(MMP7)、表面活性蛋白D(SPD)、白介素18(IL-18)和趋化因子配体18(CCL18)的血清水平与皮肌炎和多发性肌炎相关性间质性肺病(DM/PM-ILD)的关联,并评估其在疾病中的预后价值。

纳入被多学科团队诊断为DM/PM-ILD的78例患者,并根据自身抗体情况,分类为抗黑色素瘤分化相关蛋白5抗体(MDA5)-ILD、抗合成酶抗体(ARS)-ILD和其他抗体-ILD。收集临床数据并分析4种生物标志物的血清水平。主要终点为3个月死亡率。生物标志物对死亡率的阈值通过受试者工作特征(ROC)分析得出。进行Cox回归以评估预测值。

DM/PM-ILD患者的血清MMP7(p=0.036)、SPD(p<0.001)、IL-18(p<0.001)和CCL18(p<0.001)水平明显高于健康对照,并且MDA5-ILD患者的MMP7水平(p=0.029)和SPD(p=0.029)明显低于ARS-ILD患者。MDA5-ILD的3个月死亡率为54.5%(12/22)。多因素分析显示,年龄(p=0.001,HR 1.151,95%CI 1.063–1.247)和SPD水平升高(>75.90ng/ml,p=0.005,HR 16.411,95%CI 2.369–113.711)是MDA5-ILD患者3个月死亡率的重要预测指标。

血清生物标志物升高与DM/PM-ILD相关,并且MDA5-ILD和ARS-ILD之间存在差异。年龄和SPD升高可预测MDA5-ILD患者的短期死亡率。该研究为理解DM/PM-ILD的分类和预后提供了重要线索。

原始出处:

W. Lyu. Surfactant protein D is associated with 3-month mortality of anti-MDA5 antibody-interstitial lung disease. Clin Exp Rheumatol. 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1815819, encodeId=4ceb1815819b1, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Mar 03 02:19:48 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812802, encodeId=5b451812802cf, content=<a href='/topic/show?id=7e5c903000d' target=_blank style='color:#2F92EE;'>#表面活性蛋白D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90300, encryptionId=7e5c903000d, topicName=表面活性蛋白D)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 13 17:19:48 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997676, encodeId=d9d7199e67695, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Mar 06 17:19:48 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059068, encodeId=c3db205906826, content=<a href='/topic/show?id=bf2f902982a' target=_blank style='color:#2F92EE;'>#表面活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90298, encryptionId=bf2f902982a, topicName=表面活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Mon Oct 12 00:19:48 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671951, encodeId=d66316e19514c, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri May 22 04:19:48 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943557, encodeId=f0ad194355e60, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Apr 26 16:19:48 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1815819, encodeId=4ceb1815819b1, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Mar 03 02:19:48 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812802, encodeId=5b451812802cf, content=<a href='/topic/show?id=7e5c903000d' target=_blank style='color:#2F92EE;'>#表面活性蛋白D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90300, encryptionId=7e5c903000d, topicName=表面活性蛋白D)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 13 17:19:48 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997676, encodeId=d9d7199e67695, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Mar 06 17:19:48 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059068, encodeId=c3db205906826, content=<a href='/topic/show?id=bf2f902982a' target=_blank style='color:#2F92EE;'>#表面活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90298, encryptionId=bf2f902982a, topicName=表面活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Mon Oct 12 00:19:48 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671951, encodeId=d66316e19514c, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri May 22 04:19:48 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943557, encodeId=f0ad194355e60, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Apr 26 16:19:48 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1815819, encodeId=4ceb1815819b1, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Mar 03 02:19:48 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812802, encodeId=5b451812802cf, content=<a href='/topic/show?id=7e5c903000d' target=_blank style='color:#2F92EE;'>#表面活性蛋白D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90300, encryptionId=7e5c903000d, topicName=表面活性蛋白D)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 13 17:19:48 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997676, encodeId=d9d7199e67695, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Mar 06 17:19:48 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059068, encodeId=c3db205906826, content=<a href='/topic/show?id=bf2f902982a' target=_blank style='color:#2F92EE;'>#表面活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90298, encryptionId=bf2f902982a, topicName=表面活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Mon Oct 12 00:19:48 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671951, encodeId=d66316e19514c, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri May 22 04:19:48 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943557, encodeId=f0ad194355e60, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Apr 26 16:19:48 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1815819, encodeId=4ceb1815819b1, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Mar 03 02:19:48 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812802, encodeId=5b451812802cf, content=<a href='/topic/show?id=7e5c903000d' target=_blank style='color:#2F92EE;'>#表面活性蛋白D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90300, encryptionId=7e5c903000d, topicName=表面活性蛋白D)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 13 17:19:48 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997676, encodeId=d9d7199e67695, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Mar 06 17:19:48 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059068, encodeId=c3db205906826, content=<a href='/topic/show?id=bf2f902982a' target=_blank style='color:#2F92EE;'>#表面活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90298, encryptionId=bf2f902982a, topicName=表面活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Mon Oct 12 00:19:48 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671951, encodeId=d66316e19514c, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri May 22 04:19:48 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943557, encodeId=f0ad194355e60, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Apr 26 16:19:48 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1815819, encodeId=4ceb1815819b1, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Mar 03 02:19:48 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812802, encodeId=5b451812802cf, content=<a href='/topic/show?id=7e5c903000d' target=_blank style='color:#2F92EE;'>#表面活性蛋白D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90300, encryptionId=7e5c903000d, topicName=表面活性蛋白D)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 13 17:19:48 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997676, encodeId=d9d7199e67695, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Mar 06 17:19:48 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059068, encodeId=c3db205906826, content=<a href='/topic/show?id=bf2f902982a' target=_blank style='color:#2F92EE;'>#表面活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90298, encryptionId=bf2f902982a, topicName=表面活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Mon Oct 12 00:19:48 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671951, encodeId=d66316e19514c, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri May 22 04:19:48 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943557, encodeId=f0ad194355e60, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Apr 26 16:19:48 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
    2020-05-22 amy0559
  6. [GetPortalCommentsPageByObjectIdResponse(id=1815819, encodeId=4ceb1815819b1, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Mar 03 02:19:48 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812802, encodeId=5b451812802cf, content=<a href='/topic/show?id=7e5c903000d' target=_blank style='color:#2F92EE;'>#表面活性蛋白D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90300, encryptionId=7e5c903000d, topicName=表面活性蛋白D)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 13 17:19:48 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997676, encodeId=d9d7199e67695, content=<a href='/topic/show?id=bfaf55110de' target=_blank style='color:#2F92EE;'>#抗MDA5抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55110, encryptionId=bfaf55110de, topicName=抗MDA5抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Mar 06 17:19:48 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059068, encodeId=c3db205906826, content=<a href='/topic/show?id=bf2f902982a' target=_blank style='color:#2F92EE;'>#表面活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90298, encryptionId=bf2f902982a, topicName=表面活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Mon Oct 12 00:19:48 CST 2020, time=2020-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671951, encodeId=d66316e19514c, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri May 22 04:19:48 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943557, encodeId=f0ad194355e60, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Apr 26 16:19:48 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
    2020-04-26 wetgdt

相关资讯

Environmental Pollution:空气污染极有可能影响COVID-19致死率

导言:随着疫情的发展,科学家们对SARS-CoV-2的了解也越来越深入,多项研究表明,新型冠状病毒可在空气中存活数小时,并被咳嗽和打喷嚏产生的气体云带到23到27英尺之外。COVID-19传播途径与空

DCR:右结肠癌切除术后吻合口瘘与死亡率的关系

右半结肠癌切除术是结肠癌最常进行的手术之一,本项研究探究了右侧结肠癌的发病率和死亡率,并确定了右半结肠切除术后短期预后不良的预测因素。

Crit Care:危重症成人谵妄与28天和90天死亡率之间的关系

无论是谵妄发生还是谵妄天数都与入住ICU后短期死亡率无关。

J Thromb Haemost:COVID-19患者血小板减少症与死亡率的关系

血小板减少症在COVID-19患者中很常见,并且与院内死亡风险增加相关。COVID-19患者血小板数越少,死亡率越高。

钟南山:新冠死亡率6.41%,CT+AI可以预测复发

在欧洲和在美国,疫情在不断的进展,可能在未来的几周之内,会达到一个疫情的拐点。

Sci Rep:心脏手术后急性肾病的临床病程

心脏手术后的AKD与90天死亡率高和出院后肾功能下降相关。